CoPlavix Indications/Uses

Prevention of atherothrombotic events in adult patients already taking both clopidogrel and ASA. CoPlavix is a fixed-dose combination medicinal product for continuation of therapy in: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI); ST segment elevation acute MI in medically treated patients eligible for thrombolytic therapy; patients suffering from acute coronary syndrome and undergoing a stent placement following percutaneous coronary intervention.
CoPlavix (clopidogrel plus ASA fixed combination) is indicated in adults for the prevention of atherothrombotic and thromboembolic events in: Atrial Fibrillation: In patients with AF at increased risk of vascular events who can take vitamin K antagonist (VKA) therapy, VKA has been shown to be associated with a better clinical benefit than ASA alone or the combination of clopidogrel and ASA for the reduction of stroke.
In patients with atrial fibrillation who have at least 1 risk factor for vascular events and who cannot take VKA therapy [eg, specific risk of bleeding, physician assessment that patient is unable to comply with international normalised ratio (INR) monitoring or that VKA use is inappropriate], CoPlavix (clopidogrel plus ASA) is indicated for the prevention of atherothrombotic and thromboembolic events, including stroke. Clopidogrel in combination with ASA has been shown to reduce the rate of the combined endpoint of stroke, MI, non-CNS systemic embolism or vascular death, largely through a reduction in stroke (see Pharmacology: Pharmacodynamics and Clinical Efficacy/Clinical Studies under Actions).